NCT03011008

Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

Effect of Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Second Xiangya Hospital of Central South University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the therapeutic effect of Liraglutide on autoimmune diabetes.

Detailed description

Autoimmune Diabetes Mellitus (AIDM) is a subtype of diabetes mellitus caused by autoimmune destruction of beta cells in the islet, including Type 1 diabetes and Latent Autoimmune Diabetes in Adults (LADA). Insulin has been used as a routine therapy for AIDM to alleviate the hyperglycemic status, yet cannot effectively prevent the progressing destruction of beta cells or preserve its function. Glucagon-like peptide (GLP-1) analog Liraglutide has been tested in large-scale clinical trial to prove its various benefits for beta cells and glucolipid metabolism in Type 2 diabetes and obesity patients. However, its clinical application in AIDM is not well-defined so far. The aim of this study is to investigate the potential use of Liraglutide on glycemic control in AIDM.

Conditions

• Type 1 Diabetes Mellitus
• Autoimmune Diabetes

Interventions

Type	Name	Description
DRUG	Liraglutide	Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
DRUG	Insulin	Receive insulin following clinician's instruction.

Timeline

• Start date: 2017-01-01
• Primary completion: 2020-12-01
• Completion: 2021-06-01
• First posted: 2017-01-05
• Last updated: 2020-03-18

Locations

1 site across 1 country: China